ArticleJournal of experimental & clinical cancer research : CR2023

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.

Adriana Amaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.